Providing in-licensing due diligence on a Phase IIb respiratory drug

Challenge: A pharma company needed help conducting due diligence on an in-licensing/acquisition candidate for a Phase IIb respiratory drug.
Learn More

Vendor due diligence of a regulatory dossier

Challenge: A biotech company with a novel oral drug delivery technology platform was looking to out-license its lead asset, a reformulated generic therapeutic in a new, non-opioid pain, indication,...
Learn More

Oncology due diligence

Challenge: Alacrita was engaged by a strategic investor to conduct initial due diligence on a new EGFR therapeutic strategy in oncology.
Learn More

Alzheimer's due diligence for strategic investor

Challenge: Alacrita was engaged by a strategic investor to conduct initial due diligence on a novel observation and potential product opportunity in Alzheimer’s disease.
Learn More

Due diligence on generic therapeutic

Challenge A private investment firm was seeking an independent reality-check on a potential investment in a pharmaceutical company that had recently in-licensed a generic therapeutic asset. The firm...
Learn More

Dermatology due diligence and valuation

Challenge Alacrita’s pharma consultants were engaged to conduct a due diligence and valuation of a Phase II dermatology asset.
Learn More

Strategic and operational support for a start-up oncology company

Challenge A start-up company was planning to license an immunomodulatory product from a European pharmaceutical company. The therapy had been unsuccessfully tried in allergic disorders, but the...
Learn More

Conducting due diligence on a novel interventional cardiology device

Challenge A university research team had worked for a number of years on the development of a novel interventional cardiology device. Recent progress had been made with preclinical testing on pigs,...
Learn More

Due diligence on a new biosensor technology

Challenge A company considering an investment in a new early-stage biosensor technology for the measurement of blood pressure needed due diligence support. The product had a number of potential...
Learn More

Providing an oncology cell therapy reality check

Challenge A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment.
Learn More

Due diligence of a small molecule arising from a phenotypic screen

Challenge Our client asked us to conduct a risk assessment and due diligence of a small molecule oncology compound that had been identified from a phenotypic screen. The molecule was in a Phase I/II...
Learn More

Due diligence and valuation of a preclinical kinase inhibitor

Challenge We were commissioned to conduct a comprehensive technical risk assessment and due diligence of a novel preclinical, small molecule, kinase inhibitor.
Learn More